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Abstract
Histone acetyltransferases (HATs) catalyze the transfer of an acetyl group from acetyl-CoA to lysine residues of histones and
play a central role in transcriptional regulation in diverse biological processes. Dysregulation of HAT activity can lead to
human diseases including developmental disorders and cancer. Through genome-wide CRISPR-Cas9 screens, we identified
several HATs of the MYST family as fitness genes for acute myeloid leukemia (AML). Here we investigate the essentiality
of lysine acetyltransferase KAT7 in AMLs driven by the MLL-X gene fusions. We found that KAT7 loss leads to a rapid and
complete loss of both H3K14ac and H4K12ac marks, in association with reduced proliferation, increased apoptosis, and
differentiation of AML cells. Acetyltransferase activity of KAT7 is essential for the proliferation of these cells.
Mechanistically, our data propose that acetylated histones provide a platform for the recruitment of MLL-fusion-associated
adaptor proteins such as BRD4 and AF4 to gene promoters. Upon KAT7 loss, these factors together with RNA polymerase
II rapidly dissociate from several MLL-fusion target genes that are essential for AML cell proliferation, including MEIS1,
PBX3, and SENP6. Our findings reveal that KAT7 is a plausible therapeutic target for this poor prognosis AML subtype.
Introduction
Acute myeloid leukemia (AML) is an aggressive malignancy
of haematopoietic stem and progenitor cells. Translocations
involving the mixed lineage leukemia gene (MLL or KMT2A)
characterize an aggressive subtype of the disease and are
associated with an intermediate or poor prognosis [1–3].
Currently, chemotherapy based on a combination of anthra-
cyclines and purine analogs is the standard of care for AML,
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yet patients with leukemias driven by MLL-X gene fusions
commonly become refractory to such treatments [4].
Advances in our understanding of the molecular pathogen-
esis of acute leukemias driven by MLL-X fusion oncogenes
have led to the development of new drugs, including inhi-
bitors of bromodomain proteins [5–7], DOT1L [8, 9], and
MENIN [10]; however, none of these have demonstrated a
significant clinical benefit for patients as yet. In order to
identify new therapeutic approaches in AML, we and others
have performed genome-wide CRISPR-Cas9 fitness screens
in different subtypes of the disease including the MLL-X
subtype [11, 12]. Through our own screen data, we recently
showed that GCN5 (KAT2A) and SRPK1 are novel vul-
nerability in AML and that sensitivity to SRPK1 inhibition is
particularly associated with AML driven by MLL-X fusion
oncogenes [11, 13]. Systematic detailed analysis of our
CRISPR screen dataset revealed that several members of the
MYST family of histone acetyltransferases (HATs) are
required for the survival of AML cell lines, with KAT7
displaying strong essentiality for AMLs driven by MLL-X
oncogenes.
HATs are classified based on structural and sequence
homology into distinct groups including the p300/CBP,
MYST, and GCN5 families [14]. They play a central role
in transcriptional regulation through their function to
catalyze the transfer of acetyl groups from acetyl-CoA to
the ε-amino group of lysine residues of histones. Dysre-
gulation of HATs is known to be associated with human
diseases including developmental disorders and cancer
[14–16]. The MYST family of HATs, characterized by
their conserved MYST catalytic domain, includes KAT5
(TIP60), KAT6A (MOZ and MYST3), KAT6B (MORF
and MYST4), KAT7 (HBO1 and MYST2), and KAT8
(MOF) [15, 16]. While KAT6A and KAT6B are known
targets of chromosomal translocations that drive AML
[17–21] and KAT8 can play a role in some cases of AML
[22], it is currently not known whether KAT7 plays a role
in leukemogenesis. As KAT7 lacks chromatin binding
domains, it relies on forming complexes with a scaffold
protein (JADE or BRPF), along with EAF6 and ING4/5,
for efficient histone acetylation [23]. The choice of the
scaffold protein primarily determines target histones,
namely H3 or H4. The KAT7-BRPF acetylates histone H3
tails (K14 and K23) [23–26], whereas KAT7–JADE
complexes acetylates histone H4 tails (K5, K8, and K12)
[27], respectively. In development, abolishing KAT7
results in major reduction of H3K14ac in both mouse fetal
liver erythroblasts [24] and mouse embryo [25]; the latter
associates with lethality.
Here we investigate the molecular mechanism under-
lying the requirement of KAT7 in MLL-X-driven AMLs.
We report that loss of KAT7 leads to reduced proliferation
and enhanced apoptosis and differentiation. We also show
that KAT7 is essential for maintaining the transcriptional
program driven by MLL-AF9, through the recruitment of
BRD4 and other MLL-fusion associated proteins such as
AFF1 to the promoters of a subset of MLL-AF9 target
genes. Together, our findings propose KAT7 as a plausible
therapeutic target in MLL-X AML and also provide novel
mechanistic insights into the molecular basis of MLL-X-
driven transcriptional dysregulation.
Materials and methods
Cell culture
Human cell lines (MOLM-13, MV4-11, THP-1, HL-6, K562,
Nomo-1, OCI-AML2, OCI-AML3, MA9-ITD, and MA9-
RAS) and a mouse cell line (RN2) were used in this study.
All these cell lines stably express Cas9 (refs. [11, 28, 29])
and are confirmed to be mycoplasma negative. Details in
Supplementary Methods.
Proliferation assay
Cells were transduced with gRNA-expressing lentivirus and
the percentage of BFP-positive (knock-out) cells was
determined every 2 days between day 4 and day 14 using
flow cytometry. gRNA sequences used were listed in
Table S1. Details in Supplementary Methods.
Differentiation and apoptosis assays
Cells were transduced with gRNA-expressing lentivirus
and BFP-positive (knock-out) cells were collected by cell
sorting. For differentiation analysis, cells were stained with
APC-conjugated CD11b (eBioscience) 7 days post trans-
duction. For apoptosis assays, cells were analyzed 9 days
post transduction using Annexin V Apoptosis Detection
Kit APC (eBioscience). Details in Supplementary Methods.
Generation of auxin inducible degron (AID) KAT7
protein degradation system and treatment with
indole-3-acetic acid (IAA)
MOLM-13 cells were used to generate cells expressing
KAT7-AID. The resulting cells were treated with 500 μM
IAA for the duration specified for each assay. Details in
Supplementary Methods.
Western blot analysis
Western blot analysis was performed according to the
manufacturer’s instructions. Antibodies used were listed in
Table S2. Details in Supplementary Methods.
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In vivo mouse work
MOLM-13-Cas9-luc cells [11] were transduced with
gRNA-expressing lentivirus and BFP-positive cells were
sorted 2 days post transduction. On the following day, 5 ×
105 cells were injected into NSGW41 male mice. All animal
studies were carried out at the Wellcome Sanger Institute
under UK Home Office License PBF095404. Details in
Supplementary Methods.
ChIP-seq and ChIP-qPCR
MOLM-13, OCI-AML3, THP-1, and OCI-AML2 were
used for ChIP-seq and/or ChIP-qPCR analysis using anti-
bodies listed in Table S2 and qPCR primers listed in
Table S3. Details in Supplementary Methods.
RNA extraction and RNA-seq processing
RNA was extracted from AML cells with RNeasy Plus Mini
Kit (Qiagen) according to manufacturer’s instructions and
sequenced on Illumina HiSeq v4 platform with 75-bp
paired-end sequencing. Data processing and analysis were
detailed in Supplementary Methods.
Statistical analysis
Normal distribution was first tested using F-test. Student’s
t-test was used for statistical testing unless stated otherwise.
Mean was calculated from at least three replicates, as
indicated in each figure, and error bars represent the stan-
dard deviation. P values ≤ 0.05 were considered statistically
significant.
Results
Loss of KAT7 induces myeloid differentiation and
apoptosis in AML cell lines with MLL fusion
oncoprotein
We previously cataloged fitness genes in five AML cell
lines (MOLM-13, MV4-11, OCI-AML2, OCI-AML3, and
HL-60) by genome-scale CRISPR-KO screening and char-
acterized promising therapeutic targets including the histone
lysine acetyltransferase KAT2A and SRPK1 [11, 13]. We
further looked into genes encoding histone modifying
enzymes and found that several histone acetyl transferases
(HATs) were required for AML cell proliferation (Supple-
mentary Fig. S1A). Notably, two of the MYST family
HATs, KAT6A, and KAT7, were essential for AML cell
lines driven by MLL-X fusion genes: MOLM-13 (driven by
MLL-AF9), MV4-11 (MLL-AF4), and OCI-AML2 (MLL-
AF6). In order to validate these fitness defects, we first
investigated the effects on proliferation in MOLM-13 and
MV4-11 by gRNA-mediated KO and found that KAT7 loss
exhibited a consistent strong anti-proliferative effect in both
cell lines (Supplementary Fig. S1B). We then tested the
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Fig. 1 Loss of KAT7 exhibits antileukemic effects in vitro and
in vivo. a Proliferation of KAT7 KO using two sgRNAs or empty
control in MLL-X AML cell lines. Percentages of BFP-positive (KAT7-
KO) cells were assayed at the indicated time point and were normal-
ized to day 4. Data are shown as mean ± SD (n= 3). b CD11b staining
in WT (empty gRNA) and KAT7 KO (gKAT7-A10) cells 7 days post
transduction. c Annexin V/PI staining of WT (Empty) and KAT7 KO
(gKAT7-A10) cells 9 days post transduction. Data are shown as mean
± SD (n= 3). Two-tailed t-test was performed (N.S., not significant;
**P < 0.01; ***P < 0.001). d Xenograft analysis of KAT7-KO
MOLM-13. Kaplan–Meier survival analysis were performed (n= 5 in
each arm).
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impact of genetic disruption of KAT7 on proliferation of all
cell lines used in our CRISPR-KO screens and 3 additional
human leukemia cell lines, and found that, consistent with
MOLM-13 and MV4-11, KAT7 loss decreased the pro-
liferation of other MLL-X cell lines, namely OCI-AML2,
THP-1 (MLL-AF9), and Nomo-1 (MLL-AF9), but not of
MLL-WT cell lines such as OCI-AML3, HL-60, and K562
(Fig. 1a, Supplementary Fig. S1C, D). KAT7 dependency
of MLL-X leukemic cells was also confirmed in an inde-
pendently generated THP-1 Cas9 line [28], human CD34+
cells transformed by MLL-AF9 (refs. [28, 30]) and a mouse
AML cell line bearing MLL-AF9 (refs. [6, 29]) (Supple-
mentary Fig. S1E–G). The proliferation phenotype was
associated with increased expression of the myeloid dif-
ferentiation marker CD11b in MOLM-13 and OCI-AML2
(Fig. 1b, Supplementary Fig. S1H). KAT7 loss also led to an
increased apoptosis in MLL-X cell lines (Fig. 1c). Collec-
tively, these results indicate that KAT7 is required for
in vitro survival and proliferation of leukemic cells driven
byMLL-X fusion oncogenes. To assess if KAT7 inactivation
has also anti-proliferative effects in vivo, we injected
MOLM-13 cells previously transduced with a KAT7 gRNA
(KAT7-KO) into NSGW41 male mice. Mice transplanted
with KAT7-KO MOLM-13 cells showed significantly
slower AML progression and increased survival, compared
to those injected with MOLM-13 expressing a control
gRNA (Fig. 1d, Supplementary Fig. S1I), indicating the
requirement of KAT7 for in vivo proliferation.
KAT7 regulates global H3K14 and H4K12 acetylation
KAT7 is known to form two distinct HAT complexes that
acetylate either H3 or H4 (ref. [23]). We therefore investi-
gated the acetylation status of H3 and H4 tails in KAT7 KO
MOLM-13 cells. Among the potential KAT7 acetylation
sites, acetylation of Lysine-14 residue of H3 (K3K14ac) and
Lysine-12 of H4 (H4K12ac) were completely abolished
upon KAT7 KO, whereas other acetylation sites were not
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affected (Fig. 2a). We additionally investigated major his-
tone marks for active transcription, namely H3K4me3,
H3K9ac, and H3K27ac, and found that KAT7 loss did not
affect the global level of these marks (Fig. S2A). Interest-
ingly, global loss of H3K14ac and H4K12ac upon KAT7
loss was observed in all AML cell lines tested, irrespective
of the MLL translocation status or proliferation phenotype
(Fig. S2B).
Acetyltransferase activity of KAT7 is essential for
leukemic maintenance
Since both MLL-X and MLL-WT AML cell lines showed
globally reduced H3K14 and H4K12 acetylation upon
KAT7 KO but only MLL-X AML cell lines showed reduced
proliferation, we considered that noncatalytic roles of KAT7
complexes may have played a role in the observed pro-
liferative defect. To rule out such possibility, we performed
cDNA reconstitution experiments using gRNA-resistant
WT and HAT-dead KAT7 cDNAs. For the HAT-dead
KAT7 mutant, we utilized a previously characterized
E508Q MYST domain mutant [31]. To replace endogenous
KAT7 with a cDNA-derived protein, we first expressed a
gRNA-resistant KAT7 cDNA and then knocked out the
endogenous KAT7 by lentiviral transduction of KAT7
gRNA. Western blot analyses showed that control (GFP
only) MOLM-13 cells lost KAT7 as well as acetylation
marks on both H3K14 and H4K12 upon the endogenous
KAT7 KO, whereas cells carrying the WT KAT7 cDNA
retained KAT7 protein and both acetylation marks, even
after gRNA-targeting of the endogenous KAT7 gene
(Fig. 2b), indicating the appropriate reconstitution of KAT7
activity. In contrast, cells expressing HAT-dead E508Q
mutant KAT7 protein completely lost both acetylation
marks after endogenous KAT7 KO (Fig. 2b). We noted that
cells expressing both endogenous KAT7 and exogenous
HAT-dead KAT7 showed considerably reduced H4K12ac,
although H3K14ac was maintained at the level similar to
that of the control cells. This suggest a dominant negative
effect of HAT-dead KAT7 protein; however, proliferation
of MOLM-13 cells expressing either exogenous KAT7 was
not significantly different (Fig. S2C). We then analyzed
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proliferation of KAT7-reconstituted cells and found that
KAT7-WT-expressing cells did not show a proliferation
defect, ruling out the possibility that off-target effects of
KAT7 gRNAs might have been responsible for the observed
phenotype (Fig. 2c, center). In sharp contrast, the cells
expressing HAT-dead KAT7 showed proliferation defect
(Fig. 2c, right), similar to that in endogenous KAT7 KO
cells (Fig. 2c, left). This proliferation defect was associated
with increased CD11b expression (Fig. 2d). Thus, the cells
expressing HAT-dead KAT7 phenocopied the endogenous
KAT7 KO cells in histone acetylation, proliferation, and
differentiation. These results strongly indicate that KAT7-
mediated acetylation plays crucial roles in the maintenance
of the leukemic program driven by the MLL-X fusion
protein.
KAT7 loss leads to downregulation of a specific set
of MLL-AF9 target genes
In order to analyze transcriptomic changes upon KAT7 KO,
we performed RNA-seq analyses of cells transduced with
lentivirus expressing KAT7 or control gRNA (Supplemen-
tary Dataset 1). We chose MOLM-13 and OCI-AML3 as
the MLL-X positive and negative cell lines, respectively, in
this analysis. On day 3 after transduction, we observed a
total of 544 differentially expressed (DE) genes (317 up-
and 227 down-regulation) in MOLM-13 (Fig. 3a). The
number of DE genes increased further on day 5 to 4093
(1954 up- and 2139 down-regulation). In contrast, the
KAT7-independent OCI-AML3 showed only 11 genes
on day 3 and 501 on day 5. Consistent with myeloid dif-
ferentiation observed by flow cytometry (CD11b upregu-
lation, Fig. 1b), gene set enrichment analysis (GSEA)
revealed that a gene set consisting of genes upregulated
upon myeloid differentiation was significantly enriched on
days 3 and 5 (Fig. 3b, left). Concomitantly, the MLL-AF9
target gene set was significantly depleted on days 3 and 5
(Fig. 3b, center).
Through inspection of differentially expressed genes in
MOLM-13 on day 3, we identified that a small fraction of
the MLL-AF9 target genes, most notably MEIS1, PBX3,
JMJD1C, SENP6, and MEF2C, were significantly down-
regulated (Fig. 3c). Together with HOXA9, MEIS1, and
PBX3 are known to form a complex and promote tran-
scription of HOXA target genes [32]. JMJD1C and MEF2C
are also known to play an important role in MLL-AF9-
induced leukemogenesis [28, 33]. In addition, these genes
have recently been shown to be among genes, of which
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MLL-AF9 binding is not limited to their promoter region
but spreads into their gene body [34]. These MLL-X
oncoprotein “spreading” genes are collectively more sus-
ceptible to DOT1L inhibition than MLL-X “non-spreading”
genes [34], indicating that the spreading genes comprise the
core downstream network of the MLL-X-driven leukemic
program. We further performed GSEA on the expression
profiles with a gene set consisting of protein-coding KAT7-
bound MLL-AF9 spreading genes (see below, Supplemen-
tary Table S4) and found significant enrichment (Fig. 3b,
right). These enrichment was not observed in the MLL-WT,
KAT7-independent OCI-AML3 cell line.
In order to more accurately capture transcriptomic
changes immediately after KAT7 loss, we employed the
auxin-inducible degron (AID) system [35]. For this, we first
stably expressed KAT7-AID and then knocked out the
endogenous KAT7 with gRNA. We confirmed that pro-
liferation of MOLM-13 KAT7-AID was similar to that of
parental MOLM-13 cells (Supplementary Fig. S3A), indi-
cating that AID-tagged KAT7 is functional. We then
introduced OsTIR1 and treated cells with auxin IAA to
deplete KAT7 protein. The KAT7 protein level rapidly
decreased and plateaued 2 h after treatment (Fig. 4a). This
was associated with complete loss of H3K14ac over the
same time course (Fig. 4a). Cells treated with IAA showed
decreased proliferation, increased levels of apoptosis and
myeloid differentiation (CD11b) at 48 h (Fig. 4b, Supple-
mentary Fig. S3B, C). Therefore, the phenotype after IAA
treatment faithfully mirrored those seen with CRISPR-
mediated KAT7 KO (Figs. 1a–c, 2a), indicating that the
KAT7-AID system can be used to study the direct effects of
KAT7 loss.
We performed RNA-seq analysis using this MOLM-13
KAT7-AID line (Supplementary Dataset 1) and subse-
quently GSEA. After both 2- and 4-h of treatment with
IAA, there was no significant myeloid gene upregulation
(Fig. 4c, left). In contrast, enrichment of MLL-AF9
spreading genes was detectable as early as 2 h, which pre-
ceded enrichment of the entire MLL-AF9 target gene set
(Fig. 4c, center and right). These results indicate that KAT7
loss disrupts a leukemia maintenance program through
downregulation of the MLL-AF9 spreading genes and
subsequently leads to myeloid differentiation.
KAT7 binds to promoters of active genes, especially
a subset of MLL-AF9 spreading genes
We next investigated the genomic location of KAT7 bind-
ing sites using chromatin-immunoprecipitation followed by
sequencing (ChIP-seq) analysis (Supplementary Dataset 2).
We again chose MOLM-13 and OCI-AML3 for this ana-
lysis and identified 9214 and 60153 KAT7 peaks, respec-
tively. KAT7 was most enriched at promoters in both cell
lines; 63.3% of the KAT7 signals in MOLM-13 and 48.5%
in OCI-AML3 were found in promoter regions (±2 kb from
TSSs) (Supplementary Fig. 5a, b, S4A). Consistent with
previously reported ChIP-seq studies [16, 23, 24], KAT7
occupancy in the AML cell lines is significantly correlated
with the expression levels of target genes (Fig. 5a, b,
Supplementary Fig. S4B). We then focused our analysis on
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the MLL-AF9 spreading gene set. These genes are
expressed not only in the MLL-AF9-bearing MOLM-13 but
also in MLL-WT OCI-AML3 with a significant correlation
of their expression levels between the two cell lines
(Fig. S4C, r2= 0.80). As KAT7 marks expressed genes, the
majority of the MLL-AF9 spreading genes were bound by
KAT7 in both cell lines (Fig. S4D). We then compared
expression levels and KAT7 promoter occupancy of the
spreading genes (Supplementary Fig. S4E) and found that,
consistent with the genome-wide patterns, OCI-AML3
showed good correlation between the two parameters
(Supplementary Fig. S4E, right); however, MOLM-13 did
not show clear correlation, but KAT7 rather seemed to be
highly bound to a small fraction of the MLL-AF9 spreading
genes (Supplementary Fig. S4E, left). We further compared
KAT7 promoter occupancy with expression fold changes on
day 3 after KAT7 KO and found that in MOLM-13 genes
with higher KAT7 occupancy were more susceptible to and
downregulated upon KAT7 loss (Fig. 5c). In particular,
MEIS1, PBX3, JMJD1C, and SENP6, which were sig-
nificantly downregulated on day 3 (Fig. 3c), showed parti-
cularly high KAT7 promoter occupancy (Fig. 5c). There
were significant differences in KAT7 promoter occupancy
between the downregulated (n= 20) and the upregulated
(n= 4) or not-differentially expressed (n= 126) genes
(Supplementary Fig. S4F), and KAT7 was markedly enri-
ched in promoters of the KAT7-responsive MLL-
AF9 spreading genes (Supplementary Fig. S4G). In sharp
contrast and consistent with its KAT7 independence, in
OCI-AML3 KAT7 loss did not show a significant impact on
expression on day 3, even for genes with KAT7 promoter
occupancy comparable to those downregulated in MOLM-
13 (Fig. 5d, Supplementary Fig. S4F). In both cell lines, for
non-MLL-AF9 target genes, there was no significant dif-
ference in KAT7 promoter occupancy between upregulated,
downregulated and not-differentially expressed genes (Sup-
plementary Fig. S5A–D). Taken together, these results
suggest that although KAT7 is not required for general
transcription in AML, KAT7, and its acetylase activity are
required for MLL-AF9 oncoprotein to sufficiently upregu-
late and maintain expression of a specific set of the MLL-
AF9 spreading genes.
MLL-fusion associated machineries are evicted from
their target loci upon KAT7 loss
To study the consequence of KAT7 loss at the chromatin
level, we utilized the KAT7-degron system (Fig. 4, Sup-
plementary Fig. S3) and performed ChIP followed by
quantitative PCR (ChIP-qPCR) analysis. We first investi-
gated whether KAT7 is required for MLL-AF9 fusion
protein to maintain its binding to the promoters of key
MLL-AF9 spreading genes, namely JMJD1C, SENP6,
PBX3, and MEIS1, which were downregulated significantly
on day 3 after KAT7 KO (Fig. 3c) and bound by KAT7 with
markedly high occupancy (Fig. 5c). ChIP-qPCR analysis
using antibodies against MLL N-terminal and AF9
C-terminal regions 24 h after IAA treatment showed no
significant changes in their occupancy at the promoter
region (Supplementary Fig. S6A, B). This observation is
consistent with previous findings that MLL-AF9 recruit-
ment is dependent on interactions with MENIN [36],
LEDGF [37], and the PAF complex [38].
We next investigated the binding of the histone acetylation
“reader” BRD4 at gene promoters. BRD4 is a key interactor
of MLL-fusion proteins and a target of antileukemic drugs
[5, 6]. Globally, BRD4 occupancy at promoter regions is
highly correlated with KAT7 occupancy (Supplementary
Fig. S6C). At the selected key MLL-AF9 spreading genes,
KAT7, MLL-AF9, and BRD4 highly co-localized (Supple-
mentary Fig. S6D). Upon KAT7 depletion, BRD4 markedly
dissociated from the promoters of the key spreading genes
(Fig. 6a). This was associated with dissociation of AFF1,
a scaffold protein of the super elongation complex
(SEC), from these promoters (Fig. 6b). In addition, RNA
polymerase II Serine 5 phosphorylation occupancy was also
dramatically reduced at these loci (Fig. 6c). BRD4 dis-
sociation from the promoters was also confirmed in THP-1
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and OCI-AML2 (Supplementary Fig. S6E, F). These results
suggest that KAT7-mediated histone acetylation serves
as a scaffold for BRD4 binding to chromatin, which is
required for sustained recruitment of transcriptional activators
(Supplementary Fig. S7).
Discussion
Despite advances in understanding its genomics and mole-
cular pathogenesis, AML remains lethal to the majority of
sufferers [39] and anti-AML mainstream therapies have not
changed significantly for several decades. Among different
AML subtypes, cases driven by MLL-X fusion genes con-
tinue to represent an intermediate and poor prognostic
category [1–3] and despite recent developments in the field
[5, 6, 8, 10, 40] clinical progress is still lacking, empha-
sizing the need for new therapies. Here, we demonstrate that
KAT7 represents a promising novel therapeutic target for
MLL-X AML and provide insights into its function in the
maintenance of these leukemias.
KAT7-containing complexes have been shown to acet-
ylates lysine residues of histone H3 and H4 tails. Specificity
for the target histone is determined by the scaffold subunits,
BRPF and JADE. In in vitro HAT assays using nucleo-
somes, BRPF-containing complex acetylates H3K14 and
K23, while JADE-containing complex acetylates H4K5,
K8, and K12 (ref. [23]). These scaffold subunits can also
form a HAT complex with KAT6A and KAT6B and show a
similar specificity against H3 and H4 (ref. [23]). In princi-
ple, this complex formation is interchangeable, but seems
to be differentially regulated in different cell types.
For example, in HeLa cells, purified KAT7-containing
HAT complex contained JADE but not BRPF [27], and
BRPF-containing HAT complexes predominantly contain
KAT6A/B [23]. In keeping with this, knockdown of KAT7
in HeLa cells results in reduction of all of the three acet-
ylation marks on H4 (ref. [27]). In contrast, KAT7-KO in
mouse embryonic fibroblasts and KAT7 knockdown in
erythroblasts led to reduction specifically of H3K14ac
among the 5 potential acetylation sites and had no effect on
histone H4 (ref. [24, 25]). In the present study, we found
that KAT7 KO in AML cells resulted in complete loss of
both H3K14ac and H4K12ac, a pattern that has not been
described before. This strongly suggests that KAT7 is solely
responsible for acetylation of these two sites and that
KAT6A does not compensate for KAT7 loss. It has been
shown that in mouse embryos KAT6A plays a specific role
in regulating local H3K9 acetylation at the Hoxa and Hoxb
loci and is not involved in global H3K9 and H3K14 acet-
ylation [41]. This might be the case in AML cells, indi-
cating that KAT6A and KAT7 play nonoverlapping roles in
histone acetylation. KAT6A also showed fitness defects in
MLL-X AML cell lines in our analysis. It would be inter-
esting to investigate the molecular basis of KAT6A
dependency and the mechanisms by which cell-type-
specific complex formation is regulated.
Besides the general correlation between expression
level and KAT7 promoter occupancy, we found that
KAT7 strongly bound to a small subset of MLL-AF9
spreading genes in MOLM-13. The expression of this
subset is especially susceptible to KAT7 loss and it includes
well-known leukemia maintenance genes in MLL-X-driven
AML such as MEIS1, PBX3, JMJD1C, and MEF2C. MLL-
X target genes are known to be associated with high level of
H3K79me2, which is deposited by histone methyltransfer-
ase DOT1L [8, 40]. In MLL-X spreading genes,
H3K79me2 marks also spread into gene bodies, showing
broader peaks [34]. These spreading genes were shown to
be more sensitive to DOT1L inhibition than the other genes
(non-spreading and no-bound genes); the entire set of the
spreading genes are downregulated upon DOT1L inhibition
[34]. This pattern of downregulation is in sharp contrast to
the case of KAT7 loss, in which only a subset of the
spreading genes that are highly bound by KAT7 are
downregulated. Therefore, recruitment of KAT7 complex to
promoters of this subset might be regulated differently from
the rest of the promoters.
As a potential reader of H3K14ac and/or H4K12ac by
KAT7, we investigated BRD4 and showed that BRD4
dissociated from the promoter of the key spreading genes
upon KAT7 loss. BRD4 is known to play crucial roles
in maintaining MLL-X-driven leukemic programs [5, 6].
A prominent role of BRD4 in AML is to activate super-
enhancers at the MYC locus and maintain high MYC
expression [42]. Bromodomain inhibitors such as JQ1 and
i-BET151 disrupt the interaction between BRD4 and
acetylated histones, and evict BRD4 from chromatin,
thereby leading to rapid downregulation of MYC. In addi-
tion to the role at enhancers, BRD4 is known to play a role
in promoting Pol II elongation at promoter-proximal regions
by recruiting SEC including P-TEFb [42]. Accordingly, we
observed the reduced binding of AFF1 scaffold protein of
SEC upon KAT7 loss. This suggests that Pol II elongation
is severely affected, causing downregulation of target genes.
However, since the role of BRD4 at promoters is generic, it
is still unclear why only a small subset of MLL-AF9
spreading genes are affected by KAT7 loss in MOLM-13
and why gene expression is relatively stable, even in the
absence of KAT7, in the KAT7-independent OCI-AML3
cells. It is plausible that additional acetylated histone
readers are involved in KAT7-dependent transcriptional
activation for the MLL-AF9 spreading genes. From this
perspective, it is interesting to observe that pS5-Pol II
reduced its occupancy at the selected promoters. Serine 5 of
Pol II is phosphorylated by TFIIH after Pol II loading onto
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promoters [43]. Subsequent Serine 2 phosphorylation on the
C-terminal domain of Pol II by P-TEFb promotes Pol II
elongation [43]. Therefore, KAT7-mediated histone acet-
ylation may also be required for the initiation phase of Pol II
transcription. Further studies are required to elucidate the
molecular basis of KAT7-dependent transcription of MLL-
AF9 target genes.
Interestingly, a study by Sauer et al. [44] reported that
KAT7 was downregulated in patient AML samples, yet
when knocked down by shRNA, increased cell proliferation
of leukemic cell lines. Analysis using a recent large-scale
RNA-seq dataset [45] revealed no significant difference
between CD34+ cells and AML cells (Fig. S8). Moreover,
amongst 23 TCGA cancer types with matched normal
samples from the same tissue as the cancer, there were only
two cancer types, which showed significant differences in
KAT7 expression between them, namely cholangiocarci-
noma (KAT7 high in tumor) and chromophobe renal cell
carcinoma (KAT7 low in tumor). These observations sug-
gest no significant correlation between KAT7 expression
levels and neoplasia or cell proliferation. In addition, during
the revision of this paper, Dawson and colleagues reported
that KAT7 is required for the maintenance of leukemia stem
cells [46]. Their conclusion is consistent with ours and
further highlights the importance of KAT7 function in
leukemia maintenance.
Collectively, our findings reveal that KAT7 acts
upstream of BRD4 to recruit MLL-fusion associated
machineries to the promoter of key MLL-AF9 target genes,
which represent an alternative therapeutic target for MLL-X
leukemia. We anticipate that our work will motivate the
development of small-molecule inhibitors that are specific
to KAT7 and highlight KAT7 as a potential therapeutic
target for MLL-fusion AML.
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